# Epcoritamab and Rituximab for First-line Follicular Lymphoma

> **NCT05783609** · PHASE2 · RECRUITING · sponsor: **Reid Merryman, MD** · enrollment: 100 (estimated)

## Conditions studied

- Follicular Lymphoma
- Low Grade Non-Hodgkin's Lymphoma, Adult

## Interventions

- **DRUG:** Epcoritamab
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT05783609
- **Lead sponsor:** Reid Merryman, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-06-21
- **Primary completion:** 2028-02
- **Final completion:** 2030-02
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2025-12-23

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05783609

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05783609, "Epcoritamab and Rituximab for First-line Follicular Lymphoma". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05783609. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*